|
DHAA and Derivatives for Treatment of BRAF-V600E-Positive Cancer
Application
Hypolipidemic dehydroacetic acid (DHAA) treatment to prevent growth of BRAF V600E positive tumors.
Key Benefits
Treatment with slows BRAF V600E-positive tumor growth.
Repurposed compound may speed FDA approval.
May be used in combination with other therapies.
Market Summary
Up to 50% of melanoma cases harbor the BRAF V600E mutation,...
Published: 4/23/2024
Contributor(s): Jing Chen, Jack Arbiser, Brian Pollack, Siyuan Xia
|